Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities

Histone deacetylase inhibitors (HDACi) are anticancer agents that induce hyperacetylation of histones, resulting in chromatin remodeling and transcriptional changes. In addition, nonhistone proteins, such as the chaperone protein Hsp90, are functionally regulated through hyperacetylation mediated by HDACis. Histone acetylation is thought to be primarily regulated by HDACs 1, 2, and 3, whereas the acetylation of Hsp90 has been proposed to be specifically regulated through HDAC6. We compared the molecular and biologic effects induced by an HDACi with broad HDAC specificity (vorinostat) with agents that predominantly inhibited selected class I HDACs (MRLB-223 and romidepsin). MRLB-223, a potent inhibitor of HDACs 1 and 2, killed tumor cells using the same apoptotic pathways as the HDAC 1, 2, 3, 6, and 8 inhibitor vorinostat. However, vorinostat induced histone hyperacetylation and killed tumor cells more rapidly than MRLB-223 and had greater therapeutic efficacy in vivo. FDCP-1 cells dependent on the Hsp90 client protein Bcr-Abl for survival, were killed by all HDACis tested, concomitant with caspase-dependent degradation of Bcr-Abl. These studies provide evidence that inhibition of HDAC6 and degradation of Bcr-Abl following hyperacetylation of Hsp90 is likely not a major mechanism of action of HDACis as had been previously posited. Mol Cancer Ther; 12(12); 2709–21. ©2013 AACR.

[1]  S. Milstien,et al.  Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy , 2012, Oncogene.

[2]  P. Grandi,et al.  Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes , 2011, Nature Biotechnology.

[3]  P. Atadja,et al.  Treatment with Panobinostat Induces Glucose-Regulated Protein 78 Acetylation and Endoplasmic Reticulum Stress in Breast Cancer Cells , 2010, Molecular Cancer Therapeutics.

[4]  Akhilesh Pandey,et al.  Screening for therapeutic targets of vorinostat by SILAC‐based proteomic analysis in human breast cancer cells , 2010, Proteomics.

[5]  M. Mann,et al.  Lysine Acetylation Targets Protein Complexes and Co-Regulates Major Cellular Functions , 2009, Science.

[6]  J. Buggy,et al.  Isoform-specific histone deacetylase inhibitors: the next step? , 2009, Cancer letters.

[7]  Jessica E. Bolden,et al.  The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. , 2009, Blood.

[8]  E. Olson,et al.  Genetic dissection of histone deacetylase requirement in tumor cells , 2009, Proceedings of the National Academy of Sciences.

[9]  K. Subbaramaiah,et al.  HDAC6 Modulates Hsp90 Chaperone Activity and Regulates Activation of Aryl Hydrocarbon Receptor Signaling* , 2009, Journal of Biological Chemistry.

[10]  R. Johnstone,et al.  Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. , 2009, Blood.

[11]  H. Koeffler,et al.  MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. , 2008, Leukemia research.

[12]  R. Johnstone,et al.  Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin , 2008, Molecular Cancer Therapeutics.

[13]  D. Cortez,et al.  Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control. , 2008, Molecular cell.

[14]  R. Johnstone,et al.  Histone deacetylase inhibitors in lymphoma and solid malignancies , 2008, Expert review of anticancer therapy.

[15]  David Horn,et al.  Histone deacetylases. , 2008, Advances in experimental medicine and biology.

[16]  Mark J. Smyth,et al.  Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma , 2007, Proceedings of the National Academy of Sciences.

[17]  Jean-Philippe Vert,et al.  An accurate and interpretable model for siRNA efficacy prediction , 2006, BMC Bioinformatics.

[18]  Jessica E. Bolden,et al.  Anticancer activities of histone deacetylase inhibitors , 2006, Nature Reviews Drug Discovery.

[19]  N. Grishin,et al.  Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. , 2006, Molecular cell.

[20]  Satoshi Inoue,et al.  Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. , 2006, Cancer research.

[21]  Andrew J. Wilson,et al.  Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer* , 2006, Journal of Biological Chemistry.

[22]  Y. Bang,et al.  Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.

[23]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[24]  E. Seto,et al.  Acetylation and deacetylation of non-histone proteins. , 2005, Gene.

[25]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[26]  James Bradner,et al.  Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.

[27]  S. Shankar,et al.  HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma , 2005, Oncogene.

[28]  Minoru Yoshida,et al.  HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. , 2005, Molecular cell.

[29]  M. Caraglia,et al.  Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase. , 2005, Current drug targets.

[30]  Lucia Altucci,et al.  Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway , 2005, Nature Medicine.

[31]  L. Altucci,et al.  ERRATUM: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway , 2005, Nature Medicine.

[32]  I. H. Engels,et al.  Apoptosis Resistance of MCF-7 Breast Carcinoma Cells to Ionizing Radiation Is Independent of p53 and Cell Cycle Control but Caused by the Lack of Caspase-3 and a Caffeine-Inhibitable Event , 2004, Cancer Research.

[33]  P. Atadja,et al.  Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3 , 2004, Clinical Cancer Research.

[34]  P. Hersey,et al.  The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. , 2004, Molecular cancer therapeutics.

[35]  Jorge A. Almenara,et al.  Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. , 2003, Molecular cancer therapeutics.

[36]  K. Glaser,et al.  Role of class I and class II histone deacetylases in carcinoma cells using siRNA. , 2003, Biochemical and biophysical research communications.

[37]  P. Atadja,et al.  Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. , 2003, Molecular cancer therapeutics.

[38]  P. Atadja,et al.  Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. , 2003, Cancer research.

[39]  J. Trapani,et al.  Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. , 2003, Cancer research.

[40]  Ricky W Johnstone,et al.  Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? , 2003, Cancer cell.

[41]  N. Munshi,et al.  Molecular sequelae of histone deacetylase inhibition in human malignant B cells. , 2003, Blood.

[42]  Stuart L Schreiber,et al.  Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[43]  P. Matthias,et al.  HDAC‐6 interacts with and deacetylates tubulin and microtubules in vivo , 2003, The EMBO journal.

[44]  Xiao-Fan Wang,et al.  HDAC6 is a microtubule-associated deacetylase , 2002, Nature.

[45]  L. Neckers,et al.  Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. , 2002, Journal of the National Cancer Institute.

[46]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[47]  D. Bernhard,et al.  The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[48]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[49]  Tony Kouzarides,et al.  Acetylation: a regulatory modification to rival phosphorylation? , 2000, The EMBO journal.

[50]  S. Grant,et al.  Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53 , 1999, Oncogene.

[51]  D. Bernhard,et al.  Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  E. Scolnick,et al.  Growth of factor-dependent hemopoietic precursor cell lines , 1980, The Journal of experimental medicine.